SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout!
LGND 203.50-1.6%Nov 25 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: squetch who wrote (9928)10/30/1997 2:16:00 PM
From: Henry Niman  Read Replies (2) of 32384
 
Stan, I think that your guess on the DAB-fusion protein may be a good one. I looked up SRGN, and there is much overlap with LGND (targeting CTCL and psoriasis). DAB uses IL-2 (which LGND has licensed from CHIR in Canada) and EGF sends signals through STATs. I think that SRGN is just about out of money and could be bought for $10-$15 million. Do you know when approval for DAB is expected?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News